Searched for
RUBICON RESEARCH LISTING
Broader market winners! How investors found 15 multibaggers in a muted Nifty year?Despite a subdued Nifty, several Indian stocks have surged, becoming multibaggers for investors. This outperformance is attributed to resil...- Ahead of Market: 10 things that will decide stock market action on FridayIndian benchmark indices ended slightly lower amid weakness in FMCG, IT and banking stocks, while analysts highlighted improving technical ...
- Rubicon Research shares can rally 22%, says Motilal Oswal after initiating with ‘Buy’ ratingShares of Rubicon Research rose up to 3% on October 31 after Motilal Oswal initiated coverage with a ‘Buy’ rating and a target price of Rs ...
- Buy, Sell or Hold: Motilal Oswal initiates buy on Rubicon Research; Morgan Stanley recommends overweight on Aditya Birla CapitalMotilal Oswal, Goldman Sachs, and Morgan Stanley remain positive on Rubicon Research, ITC, and Aditya Birla Capital, citing strong executio...
- Healthy start! Rubicon Research shares list at 28% premium over IPO priceRubicon Research Share Price debuted on stock exchanges with a significant 27.9% premium, opening at Rs 620. The Rs 1,377 crore IPO saw ove...
- Rubicon Research to Canara HSBC Life: 6 IPO listings could offer up to 30% in next two daysSix IPOs, from pharma to insurance, are set to debut this week with grey market premiums of 0–30%; Rubicon Research leads with high subscri...
- Rubicon Research IPO allotment date today: GMP at Rs 95; How to check status on BSE and MUFG IntimeRubicon Research IPO Allotment Status: Rubicon Research's Rs 1,377 crore IPO concluded with strong investor demand, oversubscribing 109.35 ...
- Rubicon Research IPO Day 3: GMP, subscription status, brokerage views, and key highlightsRubicon Research’s IPO, backed by Arihant Capital with a “Subscribe” rating, highlights the company’s strong growth and diversified pharma ...
- IPO activity cools next week with just one new issue. Tata Capital, LG Electronics listings in focusThe Indian primary market sees a single Midwest IPO this week, alongside ongoing mainboard issues and SME offerings. Tata Capital, LG Elect...
- Rubicon Research IPO Day 2: Issue booked 2.37 times. Check GMP, other detailsRubicon Research's IPO saw strong investor demand, subscribed 2.37 times. The pharma firm specializes in generics and specialty drugs. Its ...
- Rubicon Research IPO Day 1: Subscribed 51% in initial hours – Check GMP, Brokerages' views, and key detailsRubicon Research IPO: Rubicon Research is trading at a grey market premium of ₹90, roughly 19% above the upper price band, reflecting stron...
- Rubicon Research IPO: Check GMP, brokerages review, subscription and other detailsRubicon Research's Rs 1,377 crore IPO opens on October 9. The specialty and generics pharmaceutical manufacturer offers shares at Rs 461-48...
- Tata Capital, LG Electronics India to launch IPOs worth over Rs 27,000 crore next weekThe primary market is set for a busy week as two major companies, Tata Capital Ltd and LG Electronics India Ltd, gear up to launch their in...
- IPO Calendar: LG, Tata Capital among issues worth Rs 28,500 crore to hit the Street next weekIndia's primary market prepares for a week of public issues. Five IPOs worth over Rs 28,500 crore will launch. Tata Capital and LG Electron...
- Pharma, healthcare firms eye Rs 13,000-cr IPO wave over 9 monthsIndian pharmaceutical and healthcare firms are set for a significant fundraising push, aiming to garner ₹12,000-13,000 crore through IPOs i...
- Private equity fund True North acquires minority stake in Bengaluru-based Anthem BioSet up by ex-Biocon executive Ajay Bharadwaj, Rs.1200-crore Anthem Biosciences competes with Biocon owned Syngene International and Hyderab...
- Global PE funds eye stake in GVK Bio, co valued at $800 mnIn this proposed transaction, GVK BIO- promoted by the GVK Group and DS Brar, the former CEO and managing director of Ranbaxy Laboratories,...
- Anthem Bio catches global buyout funds' eye, stake sale could see valuation rocket to $1 billionLaunched by ex-Biocon executive Ajay Bharadwaj, the Rs 1,200 crore Anthem Biosciences competes with Syngene International and GVK Bio. O3 C...
- Everstone to invest $50 million in KKR-backed Slayback PharmaEverstone joins existing institutional investor KKR, who first invested in Slayback with a $60 million commitment in December 2016.
- Kotak Private Equity may exit Rubicon with 3x returnsRubicon Research will also raise primary capital by selling another 20-25% through this round of fundraising that values the company at $20...
Load More
